Nivolumab recommended as a second-line treatment option for patients with two types of non-small-cell lung cancer

NICE draft guidance means patients with advanced squamous or non-squamous NSCLC will now be eligible for the second-line treatment on the NHS.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date

Existing members Sign in